332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II
0 activities
Bleeding in Lung Cancer Patients Receiving Therapeutic Anticoagulation While Being Treated with VEGF and EGFR Inhibitors
1 activities
Bleeding in Lung Cancer Patients Receiving Therapeutic Anticoagulation While Being Treated with VEGF and EGFR Inhibitors
Cancer-Associated Venous Thromboembolism Among Solid and Hematological Malignancies: A Comprehensive National Study
1 activities
Cancer-Associated Venous Thromboembolism Among Solid and Hematological Malignancies: A Comprehensive National Study
Challenges in Predicting Thromboembolic Risk in Acute Leukemia: Clinical Profiling and Limitations of Current Scoring Systems
1 activities
Challenges in Predicting Thromboembolic Risk in Acute Leukemia: Clinical Profiling and Limitations of Current Scoring Systems
Characteristics and Outcomes of Venous and Arterial Thromboembolism Following Cardiac Transplant: A Multi-Institutional Retrospective Study
1 activities
Characteristics and Outcomes of Venous and Arterial Thromboembolism Following Cardiac Transplant: A Multi-Institutional Retrospective Study
Clinical Significance of Incidental Central Venous Catheter-Related Thrombosis in Children Previously Treated for Cancer
1 activities
Clinical Significance of Incidental Central Venous Catheter-Related Thrombosis in Children Previously Treated for Cancer
Hospital-Acquired Venous Thromboembolism (HA-VTE) Epidemiology and Risk Factors Among Critically Ill Children and Young Adults with Diabetic Ketoacidosis
1 activities
Hospital-Acquired Venous Thromboembolism (HA-VTE) Epidemiology and Risk Factors Among Critically Ill Children and Young Adults with Diabetic Ketoacidosis
Levels, Determinants and Predictive Value of D-Dimer in Patients on Long-Term Direct Oral Anticoagulant for Venous Thrombo-Embolic Disease
1 activities
Levels, Determinants and Predictive Value of D-Dimer in Patients on Long-Term Direct Oral Anticoagulant for Venous Thrombo-Embolic Disease
Low-Molecular-Weight Heparin Benefited Outpatients with High Risk of Venous Thromboembolism Early in COVID-19 Pandemics
1 activities
Low-Molecular-Weight Heparin Benefited Outpatients with High Risk of Venous Thromboembolism Early in COVID-19 Pandemics
Peri-Procedural Anticoagulation Interruption in Acute Cancer Associated Thrombosis
1 activities
Peri-Procedural Anticoagulation Interruption in Acute Cancer Associated Thrombosis
Peripheral Blood Smear-Based Deep Learning to Predict Cancer-Associated Thrombosis
1 activities
Peripheral Blood Smear-Based Deep Learning to Predict Cancer-Associated Thrombosis
Phase 1 Study of the Safety and Pharmacodynamics of a Single Dose of Vmx-C001 in Healthy Subjects with and without FXa Direct Oral Anticoagulants
1 activities
Phase 1 Study of the Safety and Pharmacodynamics of a Single Dose of Vmx-C001 in Healthy Subjects with and without FXa Direct Oral Anticoagulants
Secondary Prophylaxis with Reduced Dose Apixaban in the Morbidly Obese
1 activities
Secondary Prophylaxis with Reduced Dose Apixaban in the Morbidly Obese
Thrombolytic Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
1 activities
Thrombolytic Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
Uncovering the Risks: Bleeding and Thrombotic Complications of JAK Inhibitors in Hematological Conditions: A Comprehensive Systematic Review and Meta-Analysis
1 activities
Uncovering the Risks: Bleeding and Thrombotic Complications of JAK Inhibitors in Hematological Conditions: A Comprehensive Systematic Review and Meta-Analysis